CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 205 enrolled
Drug / intervention
Celecoxib +4 moredrug
Likely dose
Celecoxib 400 mg orally twice daily AND eflornithine 0.5 gm/m²/day (500 mg-1,250 mg/day based on BSA)AI-extracted
Key inclusion· 5
  • Diagnosis of FAP based on >100 polyps OR >10 polyps with age <40 years OR >25 polyps with age >40 years and characteristic family history OR genetic diagnosis by IVSP or similar assay
  • Endoscopically assessable colonic and/or rectal segment at registration
  • After baseline endoscopy, must have ≥5 polyps ≥2 mm diameter in rectum OR ≥5 polyps ≥2 mm diameter in colon (including ≥3 quantifiable polyps >3 mm OR ≥2 quantifiable polyps >5 mm)
  • Willingness to abstain from NSAIDs including aspirin for duration of study; cardio-protective aspirin ≥80 mg may be permitted with PI approval
Key exclusion· 16
  • Anticipated colectomy within 8 months of randomization
  • History of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs or salicylates
  • Chronic NSAID/aspirin use in prior 6 months requires 3-month washout; must be off all NSAIDs for 3 months prior to enrollment
  • Use of fluconazole, lithium, or chronic adrenocorticosteroids

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00033371
NCT00033371Phase 2Completed

A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Sep 29, 2020

In Brief

A Phase 2 clinical trial evaluating Celecoxib, Placebo, and 3 other interventions for Colorectal Cancer and Familial Adenomatous Polyposis. Completed, enrolled 205 participants across 1 site.

Detailed Summary

This randomized phase II trial studies how well giving celecoxib with or without eflornithine works in preventing colorectal cancer in patients with familial adenomatous polyposis. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib and eflornithine may keep cancer from forming in patients with familial adenomatous polyposis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartDec 13, 2001
Primary CompletionFeb 24, 2009
Study CompletionMar 24, 2009
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 23.4 years ago

Interventions

Celecoxibdrug

Given 400 mg PO twice a day

Placeboother

Given PO to match DFMO

eflornithinedrug

Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of \> 2.6 = 1,250 mg/day).

Laboratory biomarker analysisother

Correlative studies

Questionnaire administrationother

Ancillary studies